Yan Sun - Concepedia

Author

Yan Sun

Chinese Academy of Medical Sciences & Peking Union Medical College ORCID

Also Known As

Shuxiang Zhang, Sun Y, Sun Yan, Y Sun, Y. Sun, Y. sun, YAN SUN, Yan Ping Sun, Yan SUN, Yan Sun

195

Publications

10.1K

Citations

H-Index

Concepts

All Affiliations

Chinese Academy of Medical Sciences & Peking Union Medical College Peking University Peking University Cancer Hospital Sun Yat-sen University Sun Yat-sen University Cancer Center

About

Yan Sun is an author at Chinese Academy of Medical Sciences & Peking Union Medical College specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	23	33	5.5K
2	Health Sciences	13	13	4.3K
3	Cell Biology	3	3	136
4	Public Health	1	1	13
5	Clinical Nutrition	1	1	28

Yan Sun

Publications

9.5K

Citations

H-Index

Page 1

	Year	Citations
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial Edward S. Kim, Vera Hirsh, Tony Mok, The Lancet Non-small-cell Lung CancerMedicineMetronomic TherapyClinical TrialsBronchial Neoplasm	2008	1.2K
Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial Ying Sun, Wen-Fei Li, Nian-Yong Chen, The Lancet Oncology Radiation TherapyMedicineAdvanced Nasopharyngeal CarcinomaNasopharyngeal CancerInduction Chemotherapy	2016	929
Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma Yuan Zhang, Lei Chen, Guoqing Hu, New England Journal of Medicine	2019	889
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial Lei Chen, Chaosu Hu, Xiao-Zhong Chen, The Lancet Oncology Concurrent ChemoradiotherapyRadiation TherapyMedicineAdvanced Nasopharyngeal CarcinomaCancer Management	2011	556
Neratinib, an Irreversible ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced ErbB2-Positive Breast Cancer Harold J. Burstein, Yan Sun, Luc Dirix, Journal of Clinical Oncology	2010	523
Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial Yunpeng Yang, Song Qu, Jingao Li, The Lancet Oncology MedicineClinical TrialsImmune Checkpoint InhibitorCamrelizumab Versus PlaceboPharmacotherapy	2021	429
Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial Yuankai Shi, Li Zhang, Xiaoqing Liu, The Lancet Oncology Double-blind Phase 3MedicineMetronomic TherapyClinical TrialsIcotinib Versus Gefitinib	2013	420
Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial Roy S. Herbst, Yan Sun, Wilfried Eberhardt, The Lancet Oncology Second-line TreatmentOncologyMetronomic TherapyDocetaxel Versus DocetaxelClinical Trials	2010	417
First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advancedEGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study Yuankai Shi, L. Wang, Baohui Han, Annals of Oncology Advanced Lung DiseaseMedicinePathologyImmune Checkpoint InhibitorCancer Treatment	2017	333
Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism Geoffrey A. Block, David A. Bushinsky, Sunfa Cheng, JAMA	2017	297

Page 1